MeOH); νmax/cmϪ1 (film) 3030 (C–H), 1560 (C᎐O); δ (400
Preparation of tert-butyl (3R,ꢁS)-3-(N-benzyl-N-ꢁ-methyl-4-
᎐
H
MHz, CDCl3) 2.62 [1H, dd, J2A,2B 17.1, J2A,3 1.9, C(2)HA], 3.00
[1H, dd, J2B,2A17.1, J2B,3 11.7, C(2)HB], 3.57 (1H, d, J 13.6,
NCHA), 4.16 [1H, dd, J3,2B 11.7, J3,2A 1.9, C(3)H], 4.31 (1H, d,
J 13.6, NCHA), 7.29–7.47 (10H, m, Ph); δC (100 MHz, CDCl3)
40.4, 47.4, 57.9, 128.0, 128.7, 128.8, 128.9, 129.3, 129.4, 130.6,
132.5, 135.8, 176.2; m/z APCIϩ 256.2 (MHϩ, 100%); HRMS
(CIϩ) C16H18NO2 requires 256.1338; found 256.1343.
methoxybenzylamino)pent-4-enoate 24
Following representative procedure 1, n-butyllithium (2.5 M,
6 ml, 15.1 mmol), (S)-12 (3.75 g, 15.6 mmol) in THF (20 ml)
at Ϫ78 ЊC and tert-butyl (E)-penta-2,4-dienoate (1.5 g, 9.73
mmol) in THF (30 ml) gave, after purification by chrom-
atography (hexane–Et2O 16 : 1), 24 (3.1 g, 81%) as a colourless
oil; [α]2D4 ϩ8.7 (c 1.0, CHCl3); νmax/cmϪ1 (film) 2975 (C–H), 1726
(C᎐O), 1609 (C᎐C), 1509 (OMe), 1247 (Ph–OMe); δ (400
᎐
᎐
H
Preparation of (3R,ꢁS)-3-(N-ꢁ-methyl-4-methoxybenzylamino)-
3-phenylpropionic acid 19
MHz, CDCl3) 1.36 [3H, d, J 6.8, C(α)Me], 1.39 [9H, s,
OC(Me)3], 2.27 [1H, dd, J2A,2B 14.4, J2A,3 8.9, C(2)HA], 2.34 [1H,
dd, J2B,2A 14.4, J2B,3 5.3, C(2)HB], 3.65 (2H, ABq, NCH2Ph), 3.0
(3H, s, OMe), 3.81–3.88 [1H, m, C(3)H], 3.96 [1H, q, J 6.8,
C(α)H], 5.10–5.27 [2H, m, C(5)H2], 5.89–5.98 [1H, m, C(4)H],
6.84 [2H, m, Ph(3)H, Ph(5)H C6H4OMe], 7.19–7.35 (7H, m,
Ph); δC(100 MHz, CDCl3) 12.2, 18.1, 38.5, 50.3, 55.2, 56.9, 57.2,
80.1, 113.3, 115.8, 126.5, 128.1, 128.2, 128.8, 136.2, 138.7,
141.6, 158.3, 171.2; m/z (CIϩ) 396.4 (MHϩ, 20%), 135.1
(C9H11Oϩ, 100%); HRMS (CIϩ) C25H34NO3 requires 396.2539,
found 396.2531.
Following representative procedure 3, 15 (800 mg, 2.25 mmol)
and TFA (5 ml) in DCM (6 ml) gave, after work-up and purifi-
cation by column chromatography on silica gel (CHCl3–MeOH
10 : 1), 19 (645 mg, 96%) as a white foam; [α]2D4 ϩ12.3 (c 1.0,
MeOH); νmax/cmϪ1 (film) 1642 (C᎐O), 1513 (OMe), 1203 (Ph–
᎐
OMe); δH (400 MHz, CDCl3) 1.67 [3H, d, J 6.5, C(α)Me], 2.67–
2.80 [2H, m, C(2)H2], 3.80 (3H, s, OMe), 4.12 [1H, q, J 6.4,
C(α)H], 4.54–4.59 [1H, m, C(3)H], 6.94–6.98 [2H, m, Ph(3),
Ph(5) C6H4OMe], 7.25–7.29 [2H, m, Ph(2), Ph(6) C6H4OMe],
7.43–7.52 (5H, m, Ph); δC(100 MHz, CDCl3) 19.5, 40.3, 56.3,
56.7, 59.7, 1136.1, 129.3, 130.0, 130.9, 131.2, 137.2, 162.3,
177.8; m/z APCIϩ 300.2 (MHϩ, 15%), 134.9 (C9H11Oϩ, 100%);
HRMS (CIϩ) C18H22NO5 requires 356.1599; found 356.1601.
Preparation of tert-butyl (3R,ꢁS)-3-(N-ꢁ-methyl-4-methoxy-
benzylamino)pent-4-enoate 25
Following representative procedure 2, CAN (3.9 g, 7.1 mmol)
was added to 24 (1.0 g, 2.54 mmol) in MeCN–H2O (5 : 1) (30
ml) at RT. After work-up, purification by column chrom-
atography on silica gel [hexane–Et2O (5 : 1)–1% NEt3] gave 25
(562 mg, 73%) as a colourless oil; [α]2D4 Ϫ58.6 (c 1.05, CHCl3);
νmax/cmϪ1 (film) 2973, 2835 (C–H), 1726 (C᎐O), 1609 (C᎐C),
Preparation of (4R,ꢁS)-N-(ꢁ-methyl-4-methoxybenzyl)-4-
phenylazetidin-2-one 20
Following representative procedure 4, (PyS)2 (440 mg, 2.0
mmol), PPh3 (524 mg, 2.0 mmol) and 19 (500 mg, 1.67 mmol)
were heated in refluxing MeCN (50 ml). After work-up, the
residue was purified by column chromatography on silica gel
(hexane–Et2O 1 : 1) to give 20 (391 mg, 83%) as a colourless oil;
[α]2D4 ϩ45.1 (c 1.0, CDCl3); νmax/cmϪ1 (film) 3031, 2976 (C–H),
᎐
᎐
1511 (OMe), 1243 (Ph–OMe), 1161 (C–O); δH(400 MHz,
CDCl3) 1.31 [3H, d, J 6.5, C(α)Me], 1.45 [9H, s, OC(Me)3],
2.39–2.41 [2H, m, C(2)H2], 3.49 [1H, m, C(3)H], 3.80 (3H, s,
OMe), 3.81 [1H, q, J 6.4, C(α)H], 5.07–5.17 [2H, m, C(5)H2],
5.62–5.70 [1H, m, C(4)H], 6.83–6.87 [2H, m, Ph(3)H, Ph(5)H
1746 (C᎐O), 1509 (OMe), 1245 (Ph–OMe); δ (400 MHz,
᎐
H
C6H4OMe], 7.23–7.27 [2H, d,
J 8.2, Ph(2)H, Ph(6)H
CDCl3) 1.26 [3H, d, J 7.5, C(α)Me], 2.81 [1H, dd, J3A,3B 14.5,
J3A,4 2.2, C(3)HA], 3.22 [1H, dd, J3B,3A 14.5, J3A,4 5.3, C(3)HB],
3.81 (3H, s, OMe), 5.00 [1H, q, J 7.5, C(α)H], 4.25 (1H, dd, J4,3B
5.3, J4,3A 2.2), 6.83–6.87 [2H, m, Ph(3), Ph(5) C6H4OMe], 7.11–
7.15 [2H, m, Ph(2), Ph(6) C6H4OMe], 7.27–7.37 (5H, m, Ph);
δC (100 MHz, CDCl3) 18.9, 446.2, 0.3, 51.5, 53.1, 59.7, 113.1,
129.3, 130.0, 130.9, 131.2, 137.2, 162.3, 177.8; m/z APCIϩ 282.2
(MHϩ, 100%); HRMS (CIϩ) C18H20NO2 requires 282.1494;
found 282.1489.
C6H4OMe]; δC(100 MHz, CDCl3) 23.0, 28.1, 41.3, 53.9, 55.2,
57.8, 80.5, 113.7, 115.6, 128.2, 138.1, 139.7, 158.5, 171.0; m/z
APCIϩ 306.3 (MHϩ, 15%), 135.1 (C9H11Oϩ, 100%); HRMS
(ESI) C18H28NO5 requires 306.2069; found 306.2068.
Preparation of (3R,ꢁS)-3-(N-ꢁ-methyl-4-methoxybenzylamino)-
pent-4-enoic acid 26
Following representative procedure 3, TFA (4 ml) and 25 (800
mg, 2.63 mmol) in DCM (10 ml) gave, after work-up and purifi-
cation by column chromatography on silica gel (CHCl3–MeOH
10 : 1), 26 (562 mg, 86%) as a white solid; [α]2D3 ϩ14.7 (c 1,
Preparation of (R)-4-phenylazetidin-2-one17 21
MeOH); νmax (film/cmϪ1) 1612 (C᎐O), 1516 (OMe), 1252 (Ph–
Following representative procedure 2, CAN (592 mg, 1.08
mmol) and 20 (100 mg, 0.36 mmol) in MeCN–H2O (5 : 1) gave,
after work-up and purification by column chromatography on
silica gel (hexane–Et2O 1 : 1), 21 (36 mg, 68%) as a colourless
oil; [α]2D3 ϩ136.9 (c 0.69, MeOH), [α]2D3 lit.17 ϩ132.0 (c 1, MeOH);
δH (400 MHz, CDCl3) 2.88 [1H, ddd, J3A,3B 14.0, J3A,4 2.5, J3A,NH
1.0, C(3)HA], 3.45 [1H, ddd, J3B,3A 14.0, J3B,4 5.3, J3B,NH 2.4,
C(3)HB], 4.73 [1H, dd, J4,3B 5.3, J4,3A 2.5, C(4)H], 6.30 (1H, br s,
NH), 7.31–7.42 (5H, m, Ph).
᎐
OMe); δH (500 MHz, d4-MeOH) 1.86 [3H, d, J 6.9, C(α)Me],
2.68 [1H, dd, J2A,2B 16.7, J2A,3 8.5, C(2)HA], 2.79 [1H, dd, J2B,2A
16.7, J2B,3 4.5, C(2)HB], 4.04 (3H, s, OMe), 4.21–4.25 [1H, br m,
C(3)H], 4.55 [1H, q, J 6.9, C(α)H], 5.66–5.74 [2H, m, C(5)H2],
6.00–6.07 [1H, m, C(4)H], 7.22–7.25 [2H, m, Ph(3)H and
Ph(5)H C6H4OMe], 7.60–7.63 [2H, m, Ph(2)H and Ph(6)H
C6H4OMe]; δC (125 MHz, d4-MeOH) 19.2, 36.7, 56.2, 56.3,
58.5, 116.2, 123.4, 130.0, 131.3, 133.8, 162.4, 177.6; m/z APCIϩ
250.2 (MHϩ, 30%), 135.1 (C9H11Oϩ, 100%); HRMS (ESI)
C14H19NO3Na requires 272.1263; found 272.1272.
Preparation of (R)-N-benzyl-4-phenylazetidin-2-one18 22
Following representative procedure 4, (PyS)2 (311 mg, 1.2
mmol), PPh3 (370 mg, 1.41 mmol) and 18 (300 mg, 1.18 mmol)
were heated in refluxing MeCN (50 ml). After work-up, the
residue was purified by column chromatography on silica gel
(hexane–Et2O 2 : 1) to give 22 (228 mg, 82%) as a colourless oil;
[α]2D3 ϩ94.5 (c 1.0, MeOH), [α]2D3 lit. (ent-22)18 Ϫ54.4 (c 0.59,
MeOH); δH (400 MHz, CDCl3) 2.87 [1H, dd, J3A,3B 14.7, J3A,4
1.7, C(3)HA], 3.35 [1H, dd, J3B,3A 14.7, J3A,4 5.5, C(3)HB], 3.76
(1H, d, J 15.1, NCHA), 4.40 [1H, dd, J4,3B 5.5, J4,3A 1.7, C(4)H],
4.81 (1H, d, J 15.1, NCHB), 7.13–7.16 (2H, m, Ph), 7.25–7.39
(8H, m, Ph).
Preparation of (4R,ꢁS)-N-(ꢁ-methyl-4-methoxybenzyl)-4-
vinylazetidin-2-one 27
Following representative procedure 4, (PyS)2 (425 mg, 1.93
mmol), PPh3 (505 mg, 1.93 mmol) and 26 (400 mg, 1.61 mmol)
were heated in refluxing MeCN (80 ml). After cooling and con-
centration of the reaction in vacuo, column chromatography of
the residue on silica gel (Et2O–hexane 1 : 1) gave 27 (325 mg,
87%) as a colourless oil; [α]2D4 Ϫ97.0 (c 1.05, CHCl3); νmax/cmϪ1
(film) 2976 (C–H), 1746 (C᎐O), 1513 (OMe), 1244 (Ph–OMe);
᎐
δH(400 MHz, CDCl3) 1.54 [3H, d, J 7.2, C(α)Me], 2.62 [1H, dd,
3110
J. Chem. Soc., Perkin Trans. 1, 2001, 3106–3111